Novo Nordisk Slashes Wegovy Prices for US Patients

Novo Nordisk is introducing a new subscription plan for its Wegovy obesity drug in the U.S., offering discounted monthly prices for self-pay patients. Launched on Tuesday, the program allows eligible individuals to purchase three-, six-, or 12-month supplies at reduced fixed rates, with longer commitments providing greater savings. This initiative represents a strategic move to enhance market access and to counter competition from Eli Lilly, particularly in the rapidly expanding obesity treatment sector.

The discounted pricing ranges from approximately 6% to 29% below the standard $349 monthly cost for Wegovy injection pens, and 3% to 17% below the $299 monthly price for the Wegovy pill. These new prices aim to make the treatment more affordable for consumers seeking obesity management solutions. Novo Nordisk's strategy includes partnerships with telehealth platforms like Ro, WeightWatchers, and LifeMD, with more expected to join.

This pricing adjustment is part of a broader effort by Novo Nordisk to navigate a competitive landscape increasingly influenced by direct-to-consumer sales and telehealth services. The company has made significant organizational changes, including new leadership in its U.S. business, to strengthen its market position against rivals like Eli Lilly. The focus is on adapting to the evolving role of patients as consumers who prioritize clear pricing and budget-friendly options.